Matinas Biopharma

[Not Yet Scheduled]
Matinas BioPharma is a biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. Matinas' lead asset is MAT2203, an oral LNC formulated amphotericin B currently in Phase 2 with a planned pivotal to start in 2022.
Ticker:
MTNB
Exchange:
NYSE
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
MAT2203 oral amphotericin B
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2- MAT2203 and LNC platform
Speaker
photo
Chief Business Officer
Matinas BioPharma, Inc.